Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is withdrawing approval of ten abbreviated new drug applications (ANDAs) held by Able Laboratories, Inc. (Able Labs), One Able Dr., Cranbury, NJ 08512. Able Labs has initiated a class II recall of the products covered by these ANDAs. The company has requested that the applications be withdrawn and has waived its opportunity for a hearing.
Effective August 29, 2005.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Florine P. Purdie, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.End Further Info End Preamble Start Supplemental Information
On May 25, 2005, Able Labs notified the agency that, because of improper laboratory practices and noncompliance with standard operating procedures, Able Labs was initiating a voluntary, class II recall of the products covered by the ANDAs listed in the table of this document. The company voluntarily requested withdrawal of approval of the ANDAs under § 314.150(d) (21 CFR 314.150(d)), and waived its opportunity for a hearing, provided under § 314.150(a) and (b). The following ANDAs are affected by this action:
|40-395||Diphenoxylate Hydrochloride (HCl) and Atropine Sulfate Tablets USP, 2.5 milligrams (mg)/0.025 mg|
|40-404||Methylphenidate HCl Tablets USP, 5 mg, 10 mg, and 20 mg|
|40-407||Prochlorperazine Suppositories USP, 2.5 mg, 5 mg, and 25 mg|
|40-452||Acetaminophen and Codeine Phosphate Tablets USP, 300 mg/30 mg|
|40-459||Acetaminophen and Codeine Phosphate Tablets USP, 300 mg/60 mg|
|71-780||Clorazepate Dipotassium Tablets USP, 3.75 mg|
|71-781||Clorazepate Dipotassium Tablets USP, 7.5 mg|
|71-782||Clorazepate Dipotassium Tablets USP, 15 mg|
|Start Printed Page 51076|
|75-838||Propoxyphene Napsylate and Acetaminophen Tablets USP, 100 mg/650 mg|
|76-032||Methylphenidate HCl Exended-Release Tablets USP, 20 mg|
Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.105(a)), approval of the ANDAs listed in the table of this document, and all amendments and supplements thereto, is withdrawn, effective August 29, 2005. Thereafter, distribution of the products in interstate commerce without approved applications is illegal and subject to regulatory action. Also, on the basis of the circumstances described in this document that led to the recall of the products and their subsequent removal from the market, the agency will remove the products from the agency's list of drug products with effective approvals, published under the title “Approved Drug Products With Therapeutic Equivalence Evaluations.” This document serves as notice of the removal of the products covered by the ANDAs listed in this document from the list of approved drug products. Distribution of these products in interstate commerce without approved applications is illegal and subject to regulatory action (see sections 505(a) and 301(d) of the act (21 U.S.C. 355(a) and 331(d)).Start Signature
Dated: August 15, 2005.
Director, Center for Drug Evaluation and Research.
[FR Doc. 05-17151 Filed 8-26-05; 8:45 am]
BILLING CODE 4160-01-S